Lethal congenital contracture syndrome type 3

Lethal congenital contracture syndrome type 3 (LCCS3), also known as lethal congenital contracture syndrome 3, is an extremely rare and severe autosomal recessive disorder characterized by multiple joint contractures (arthrogryposis), fetal akinesia (reduced or absent fetal movement), and lethality in the prenatal or neonatal period. The condition belongs to a group of Finnish heritage lethal congenital contracture syndromes, though LCCS3 has been identified in non-Finnish populations as well. It is caused by mutations in the PIP5K1C gene, which encodes phosphatidylinositol-4-phosphate 5-kinase type 1 gamma, an enzyme important for synaptic vesicle recycling and neuromuscular function. Clinically, affected fetuses and neonates present with severe multiple contractures involving both upper and lower limbs, markedly reduced fetal movements detectable on prenatal ultrasound, micrognathia (small jaw), and in some cases additional features such as pterygia (webbing of skin across joints), pulmonary hypoplasia, and hydrops fetalis. The musculoskeletal and nervous systems are primarily affected, with the underlying pathology believed to involve impaired neuromuscular transmission and anterior horn cell degeneration in the spinal cord. The condition is invariably lethal, with death occurring either in utero or shortly after birth. There are currently no curative treatments or disease-modifying therapies available for LCCS3. Management is limited to supportive and palliative care. Genetic counseling is essential for affected families, as carrier parents have a 25% recurrence risk with each pregnancy. Prenatal diagnosis through molecular genetic testing or ultrasound monitoring may be offered to families with a known mutation.

Common questions about Lethal congenital contracture syndrome type 3